Biotech Values

[dewophile]

i'll give it a crack:

scenario 1: i agree this deserves mammoth valuation, not just because of the raw revenue stream to the company from being the sole generic, but due to validation of the platform (i.e. the FDA is saying MNTA can characterize the complex sugars in a satisfactory manner to prove "equvalence" in a way others can't - which also has carryover to the FoB arena in general, where variations in glycosylation is the main sticking point)

scenario 2: i think your valuation is excessive, mainly because of the reverse of the situation i lay out above - now the FDA is saying anyone can characterize sugars well enough to produce generics, and there is nothing special per se about MNTA's proprietary technology

case 3: MNTA slowly but surely drifts lower and lower as there seems to be no end in sight to the regulatory quagmire surrounding complex generics/FoBs

case 4: MNTA trades for little more than cash, as the entire EV is based on M118, which is itself questioned due to concerns surrounding the platform